# EDGAR Filing Document

**Accession Number:** 0001871563
**File Stem:** 0001209191-23-008557
**Filing Date:** 2023-2
**Character Count:** 10734
**Document Hash:** 5d2a8e35cd01527ed7cb46b6e0736cd1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-008557.hdr.sgml**: 20230210

**ACCESSION NUMBER**: 0001209191-23-008557

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221115

**FILED AS OF DATE**: 20230210

**DATE AS OF CHANGE**: 20230210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Simantov Ronit
- **CENTRAL INDEX KEY:** 0001871563

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38716
- **FILM NUMBER:** 23614182

**MAIL ADDRESS:**
- **STREET 1:** 1988 CHAPEL STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06515
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Gamida Cell Ltd.
- **CENTRAL INDEX KEY:** 0001600847
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 5 NAHUM HAFZADI STREET
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 95484
- **BUSINESS PHONE:** 97226595666

**MAIL ADDRESS:**
- **STREET 1:** 5 NAHUM HAFZADI STREET
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 95484

## Ex-24

```

Exhibit 24

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

	Know all by these presents, that the undersigned hereby constitutes and
appoints each of Wouter Deleersnyder, Dayne A. Brown and Cathy Rude of Cooley
LLP, and Joshua F. Patterson of Gamida Cell Ltd. (the "Company"), signing
individually, the undersigned's true and lawful attorneys-in-fact and agents to:

	(1)	Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the Securities and Exchange Commission (the "SEC") a Form ID,
Uniform Application for Access Codes to File on EDGAR, including amendments
thereto, and any other documents necessary or appropriate to obtain codes and
passwords enabling the undersigned to make electronic filings with the SEC of
reports required by Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or any rule or regulation thereunder;

	(2)	Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the SEC Form ID and Forms 3, 4 and 5 (including amendments thereto
and joint filing agreements in connection therewith) in accordance with Section
16(a) of the Exchange Act and the rules thereunder in the undersigned's capacity
as an officer, director or beneficial owner of more than 10% of a registered
class of securities of the Company;

	(3)	Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form ID and Forms
3, 4 or 5 (including amendments thereto and joint filing agreements in
connection therewith) and file such forms with the SEC and any stock exchange,
self-regulatory association or any similar authority; and

	(4)	Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Form ID or Forms
3, 4 and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, (b) revocation by the undersigned in a signed
writing delivered to the Company and the foregoing attorneys-in fact or (c) as
to any attorney-in-fact individually, until such attorney-in-fact is no longer
employed by the Company or Cooley LLP, as applicable.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Date: October 29, 2021
/s/ Ronit Simantov
Name: Ronit Simantov

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Simantov Ronit<br><sub>(Last) (First) (Middle)</sub><br>C/O GAMIDA CELL LTD.<br>116 HUNTINGTON AVENUE<br><sub>(Street)</sub><br>BOSTON, MA 02116<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Gamida Cell Ltd. [ GMDA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2022-11-15 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_CMO & Chief Scientific Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares<sup>(1)</sup> | 117477<sup>(2)(3)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Share Option (Right to Buy) | <sup>(4)</sup> | 2027-11-16 | Ordinary Shares | 186574 | $4.90 | D |  |
| Employee Share Option (Right to Buy) | <sup>(5)</sup> | 2029-03-11 | Ordinary Shares | 49400 | $11.01 | D |  |
| Employee Share Option (Right to Buy) | <sup>(6)</sup> | 2030-02-24 | Ordinary Shares | 49000 | $4.70 | D |  |
| Employee Share Option (Right to Buy) | <sup>(7)</sup> | 2031-02-25 | Ordinary Shares | 54000 | $9.51 | D |  |
| Employee Share Option (Right to Buy) | <sup>(8)</sup> | 2032-01-28 | Ordinary Shares | 79700 | $2.93 | D |  |

---

### Footnotes:

(1) The Reporting Person became a Section 16 officer, effective November 15, 2022. This report discloses ordinary shares beneficially owned by the Reporting Person as of the date on which the Reporting Person became subject to the reporting obligation on Form 3 under Section 16 of the Securities Exchange Act of 1934, as amended.

(2) Includes an award of 13,300 restricted share units, 33% of which vested on January 28, 2023, 33% of which shall vest on January 28, 2024 and 34% of which shall vest on January 28, 2025, subject to the Reporting Person's continuous service through each such vesting date.

(3) Includes an award of 38,800 restricted share units, 50% of which vested on January 28, 2023 and 50% of which shall vest on January 28, 2024, subject to the Reporting Person's continuous service through such vesting date.

(4) Immediately exercisable.

(5) One fourth (1/4th) of the shares subject to the option award vested on March 13, 2020, and one twelfth (1/12th) of the remaining shares subject to the optionaward vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

(6) One fourth (1/4th) of the shares subject to the option award vested on February 24, 2021, and one twelfth (1/12th) of the remaining shares subject to the optionaward vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

(7) One fourth (1/4th) of the shares subject to the option award vested on February 25, 2022, and one twelfth (1/12th) of the remaining shares subject to the option award vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

(8) One fourth (1/4th) of the shares subject to the option award shall vest on January 28, 2023, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

**Remarks:**
Exhibit List - Exhibit 24 - Power of Attorney

**Signature:** /s/ Joshua F. Patterson, Attorney-in-Fact  
**Date:** 2023-02-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**